Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Werewolf Therapeutics, Inc. (HOWL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors&#59; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 -"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors&#59; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 -"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update -Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors-"
03/22/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "First Amendment to Amended and Restated Loan and Security Agreement, by and between the Company and Pacific Western Bank",
"First Amendment to Amended and Restated Loan and Security Agreement, by and between the Company and Pacific Western Bank"
02/10/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/17/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/17/2023 SC 13G/A PFM Health Sciences, LP reports a 4.2% stake in Werewolf Therapeutics, Inc.
01/10/2023 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 18% stake in Werewolf Therapeutics, Inc.
01/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Dosed first patient in Phase 1/1b study evaluating WTX-124 as a monotherapy and in combination with KEYTRUDA® in advanced solid tumors&#59; initial data anticipated in the fourth quarter of 2023 -"
09/07/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from Deloitte & Touche LLP",
"Letter from Deloitte & Touche LLP"
08/12/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/23/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/10/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
Docs: "Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights - Entered exclusive global license and collaboration agreement with Jazz Pharmaceuticals to develop and commercialize WTX-613&#59; received $15.0M upfront payment and eligibility for up to $1.26B in downstream milestones as well as royalties on potential future sales -"
05/02/2022 SC 13G PFM Health Sciences, LP reports a 5.5% stake in Werewolf Therapeutics, Inc.
04/22/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/22/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/15/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Amended and Restated Loan and Security Agreement, by and between the Registrant and Pacific Western Bank",
"Amended and Restated Loan and Security Agreement, by and between the Registrant and Pacific Western Bank"
04/07/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/24/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/24/2022 10-K Annual Report for the period ended December 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy